• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Dan G. Duda


  • Richter C, Seco J, Hong TS, Duda DG, Bortfeld T.Radiation-induced changes in hepatocyte-specific Gd-EOB-DTPA enhanced MRI: Potential mechanism.Med Hypotheses. 2014 Oct;83(4):477-81.
  • Stroh M, Duda DG, Takimoto CH, Yamazaki S, Vicini P.Translation of anticancer efficacy from nonclinical models to the clinic.CPT Pharmacometrics Syst Pharmacol. 2014;3:e128.
  • Duda DG, Ancukiewicz M, Isakoff SJ, Krop IE, Jain RK.Seeds and soil: unraveling the role of local tumor stroma in distant metastasis.Journal of the National Cancer Institute. 2014 Aug;106(8).
  • Hato T, Goyal L, Greten TF, Duda DG, Zhu AX.Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions.Hepatology. 2014 Jun 9.
  • Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, Wadlow RC, Kwak EL, Allen JN, Clark JW, Zhu AX, Ferrone CR, Mamon HJ, Adams J, Winrich B, Grillo T, Jain RK, DeLaney TF, Fernandez-Del Castillo C, Duda DG.A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma.Int J Radiat Oncol Biol Phys. 2014 May 24.
  • Cucu D, Chiritoiu G, Petrescu S, Babes A, Stanica L, Duda DG, Horii A, Dima SO, Popescu I.Characterization of Functional Transient Receptor Potential Melastatin 8 Channels in Human Pancreatic Ductal Adenocarcinoma Cells.Pancreas. 2014 Mar 20.
  • Huang Y, Stylianopoulos T, Duda DG, Fukumura D, Jain RK.Benefits of vascular normalization are dose and time dependent--letter.Cancer Res. 2013 Dec 1;73(23):7144-6.
  • Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK.Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19059-64.
  • Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG.Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1α/CXCR4 axis and Gr-1+ myeloid cell infiltration in mice.Hepatology. 2013 Nov 14.
  • Chan-On W, Nairismägi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D, Sithithaworn P, Yongvanit P, Wongkham S, Khuntikeo N, Bhudhisawasdi V, Popescu I, Rozen SG, Tan P, Teh BT.Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.Nat Genet. 2013 Nov 3.
  • Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG, Stuart K.A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer.Clin Cancer Res. 2013 Nov 11.
  • Goel S, Gupta N, Walcott BP, Snuderl M, Kesler CT, Kirkpatrick ND, Heishi T, Huang Y, Martin JD, Ager E, Samuel R, Wang S, Yazbek J, Vakoc BJ, Peterson RT, Padera TP, Duda DG, Fukumura D, Jain RK.Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression.Journal of the National Cancer Institute. 2013 Aug 21;105(16):1188-201.
  • Samuel R, Daheron L, Liao S, Vardam T, Kamoun WS, Batista A, Buecker C, Schäfer R, Han X, Au P, Scadden DT, Duda DG, Fukumura D, Jain RK.Generation of functionally competent and durable engineered blood vessels from human induced pluripotent stem cells.Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12774-9.
  • Sahani DV, Jiang T, Hayano K, Duda DG, Catalano OA, Ancukiewicz M, Jain RK, Zhu AX.Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.J Hematol Oncol. 2013;6:51.
  • Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov AO, Batchelor TT, Jain RK.Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.Neuro Oncology. 2013 Aug;15(8):1079-87.
  • Duda DG, Munn LL, Jain RK.Can We Identify Predictive Biomarkers for Antiangiogenic Therapy of Cancer Using Mathematical Modeling?.Journal of the National Cancer Institute. 2013 May 13.
  • Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG.Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.Clin Cancer Res. 2013 Mar 15;19(6):1557-66.
  • Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R, Huang Y, Martin JD, Kamoun W, Knevels E, Schmidt T, Farrar CT, Vakoc BJ, Mohan N, Chung E, Roberge S, Peterson T, Bais C, Zhelyazkova BH, Yip S, Hasselblatt M, Rossig C, Niemeyer E, Ferrara N, Klagsbrun M, Duda DG, Fukumura D, Xu L, Carmeliet P, Jain RK.Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma.Cell. 2013 Feb 28;152(5):1065-76.
  • Huang Y, Goel S, Duda DG, Fukumura D, Jain RK.Vascular normalization as an emerging strategy to enhance cancer immunotherapy.Cancer Res. 2013 Feb 25.
  • Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC.Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6.
  • Duda DG, Willett CG.Going beyond systemic fluoropyrimidines with radiation therapy for rectal cancer: what should be the priority?.Oncology (Huntingt). 2012 Aug;26(8):741-3.
  • Dima SO, Tanase C, Albulescu R, Herlea V, Chivu-Economescu M, Purnichescu-Purtan R, Dumitrascu T, Duda DG, Popescu I.An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma.Pancreas. 2012 Oct;41(7):1001-7.
  • Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG.Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.PLoS ONE. 2012;7(6):e38231.
  • Kozin SV, Duda DG, Munn LL, Jain RK.Neovascularization After Irradiation: What is the Source of Newly Formed Vessels in Recurring Tumors?.Journal of the National Cancer Institute. 2012 May 9.
  • Duyverman AM, Kohno M, Roberge S, Fukumura D, Duda DG, Jain RK.An isolated tumor perfusion model in mice.Nat Protoc. 2012;7(4):749-55.
  • Duyverman AM, Steller EJ, Fukumura D, Jain RK, Duda DG.Studying primary tumor-associated fibroblast involvement in cancer metastasis in mice.Nat Protoc. 2012;7(4):756-62.
  • Duyverman AM, Kohno M, Duda DG, Jain RK, Fukumura D.A transient parabiosis skin transplantation model in mice.Nat Protoc. 2012;7(4):763-70.
  • Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG.Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.Oncologist. 2012;17(2):212-9.
  • Raut CP, Boucher Y, Duda DG, Morgan JA, Quek R, Ancukiewicz M, Lahdenranta J, Eder JP, Demetri GD, Jain RK.Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).PLoS ONE. 2012;7(2):e26331.
  • Horowitz NS, Penson RT, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Cohen KS, Berlin S, Krasner CN, Moses MA, Jain RK.Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.Clinical Ovarian Cancer And Other Gynecologic Malignancies. 2011 Jun;4(1):26-33.
  • Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK.Normalization of the vasculature for treatment of cancer and other diseases.Physiol. Rev. 2011 Jul;91(3):1071-121. Review.
  • Kozin SV, Duda DG, Munn LL, Jain RK.Is vasculogenesis crucial for the regrowth of irradiated tumours?.Nat Rev Cancer. 2011;11(7):532.
  • Zhu AX, Duda DG, Sahani DV, Jain RK.HCC and angiogenesis: possible targets and future directions.Nat Rev Clin Oncol. 2011 Mar 8.
  • Hiratsuka S, Goel S, Kamoun WS, Maru Y, Fukumura D, Duda DG, Jain RK.Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation.Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3725-30.
  • Duda DG, Kozin S, Kirkpatrick ND, Xu L, Fukumura D, Jain RK.CXCL12 (SDF1α) - CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anti-Cancer Therapies?.Clin Cancer Res. 2011 Feb 24.
  • Hiratsuka S, Duda DG, Huang Y, Goel S, Sugiyama T, Nagasawa T, Fukumura D, Jain RK.C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells.Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):302-7.
  • Dawson MR, Chae S-S, Jain RK, Duda DG.Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression.Am J Cancer Res. 2011;1(2):144-54.
  • di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK.Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.Cancer Res. 2011 Jan 1;71(1):19-28.
  • Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, Jain RK.Malignant cells facilitate lung metastasis by bringing their own soil.Proc Natl Acad Sci U S A. 2010 Nov 22.
  • Yoon SS, Duda DG, Karl DL, Kim TM, Kambadakone AR, Chen YL, Rothrock C, Rosenberg AE, Nielsen GP, Kirsch DG, Choy E, Harmon DC, Hornicek FJ, Dreyfuss J, Ancukiewicz M, Sahani DV, Park PJ, Jain RK, Delaney TF.Phase II Study of Neoadjuvant Bevacizumab and Radiotherapy for Resectable Soft Tissue Sarcomas.Int J Radiat Oncol Biol Phys. 2010 Oct 5.
  • Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, Fuchs CS, Ryan DP, Jain RK.Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value.Clin Cancer Res. 2010 Sep 15.
  • Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT.Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.J. Neurooncol. 2010 Sep 7.
  • Willett CG, Duda DG, Ancukiewicz M, Shah M, Czito BG, Bentley R, Poleski M, Fujita H, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Chung DC, Clark JW, Jain RK.A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared with Standard Chemoradiation in Locally Advanced Rectal Cancer.Oncologist. 2010;15(8):845-51.
  • Duda DG, Jain RK.Premetastatic Lung "Niche": Is Vascular Endothelial Growth Factor Receptor 1 Activation Required?.Cancer Res. 2010 Jul 15;70(14):5670-3. Review.
  • Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG.Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation.Cancer Res. 2010 Jul 15;70(14):5679-85.
  • Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Clark JW, Jain RK.Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.Oncologist. 2010;15(6):577-83.
  • Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK.Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.J Clin Oncol. 2010 Jun 10;28(17):2817-23.
  • Fukumura D, Duda DG, Munn LL, Jain RK.Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models.Microcirculation. 2010 Apr;17(3):206-25. Review.
  • Jones R,Capen DE,Jacobson M,Cohen KS,Scadden DT,Duda DG.VEGFR2PDGFRbeta circulating precursor cells participate in capillary restoration after hyperoxia acute lung injury (HALI).J Cell Mol Med. 2009 Sep;13(9B):3720-9.
  • Duda DG, Ancukiewicz M, Jain RK.Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?.J Clin Oncol. 2010 Jan 10;28(2):183-5.
  • Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin PC, Poleski M, Bentley R, Clark JW, Willett CG, Jain RK.Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.Cancer Res. 2009 Oct 15;69(20):7905-10.
  • Dawson MR, Duda DG, Chae SS, Fukumura D, Jain RK.VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation.PLoS ONE. 2009;4(9):e6525.
  • Dawson MR, Duda DG, Fukumura D, Jain RK.VEGFR1-activity-independent metastasis formation.Nature. 2009 Sep 17;461(7262):E4; discussion E5.
  • Zhu AX, Duda DG, Sahani DV, Jain RK.Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.Cancer J.;15(4):263-8. Review.
  • Woodward WA,Bristow RG,Clarke MF,Coppes RP,Cristofanilli M,Duda DG,Fike JR,Hambardzumyan D,Hill RP,Jordan CT,Milas L,Pajonk F,Curran WJ,Dicker AP,Chen Y.Radiation Therapy Oncology Group Translational Research Program Stem Cell Symposium: Incorporating Stem Cell Hypotheses into Clinical Trials.Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1580-91.
  • Sorensen AG,Batchelor TT,Zhang WT,Chen PJ,Yeo P,Wang M,Jennings D,Wen PY,Lahdenranta J,Ancukiewicz M,di Tomaso E,Duda DG,Jain RK.A "Vascular Normalization Index" as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients.Cancer Res. 2009 Jul 1;69(13):5296-300.
  • Au P,Tam J,Duda DG,Lin PC,Munn LL,Fukumura D,Jain RK.Paradoxical Effects of PDGF-BB Overexpression in Endothelial Cells on Engineered Blood Vessels In Vivo.Am J Pathol. 2009 Jul;175(1):294-302.
  • Zhu AX,Sahani DV,Duda DG,di Tomaso E,Ancukiewicz M,Catalano OA,Sindhwani V,Blaszkowsky LS,Yoon SS,Lahdenranta J,Bhargava P,Meyerhardt J,Clark JW,Kwak EL,Hezel AF,Miksad R,Abrams TA,Enzinger PC,Fuchs CS,Ryan DP,Jain RK.Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study.J Clin Oncol. 2009 Jun 20;27(18):3027-35.
  • Willett CG,Duda DG,di Tomaso E,Boucher Y,Ancukiewicz M,Sahani DV,Lahdenranta J,Chung DC,Fischman AJ,Lauwers GY,Shellito P,Czito BG,Wong TZ,Paulson E,Poleski M,Vujaskovic Z,Bentley R,Chen HX,Clark JW,Jain RK.Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study.J Clin Oncol. 2009 Jun 20;27(18):3020-6.
  • Jain RK,Duda DG,Willett CG,Sahani DV,Zhu AX,Loeffler JS,Batchelor TT,Sorensen AG.Biomarkers of response and resistance to antiangiogenic therapy.Nat Rev Clin Oncol. 2009 Jun;6(6):327-338. Review.
  • Kamoun WS,Ley CD,Farrar CT,Duyverman AM,Lahdenranta J,Lacorre DA,Batchelor TT,di Tomaso E,Duda DG,Munn LL,Fukumura D,Sorensen AG,Jain RK.Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.J Clin Oncol. 2009 May 20;27(15):2542-52.
  • Tam J,Duda DG,Perentes JY,Quadri RS,Fukumura D,Jain RK.Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells.PLoS ONE. 2009;4(3):e4974.
  • Gerstner ER,Duda DG,di Tomaso E,Ryg PA,Loeffler JS,Sorensen AG,Ivy P,Jain RK,Batchelor TT.VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.Nat Rev Clin Oncol. 2009 Apr;6(4):229-36. Review.
  • Perentes JY,Duda DG,Jain RK.Visualizing anti-tumor immune responses in vivo.Dis Model Mech. 2009 Mar;2(3-4):107-10.
  • Huang P,Duda DG,Jain RK,Fukumura D.Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice.Comp Med. 2008 Jun;58(3):253-63.
  • Jones RC, Capen DE, Cohen KS, Munn LL, Jain RK, Duda DG.A protocol for phenotypic detection and characterization of vascular cells of different origins in a lung neovascularization model in rodents.Nat Protoc. 2008;3(3):388-97.
  • Jones RC, Capen D, Petersen B, Jain RK, Duda DG.A protocol for a lung neovascularization model in rodents.Nat Protoc. 2008;3(3):378-87.
  • Gerstner ER, Duda DG, di Tomaso E, Sorensen G, Jain RK, Batchelor TT.Antiangiogenic agents for the treatment of glioblastoma.Expert Opin Investig Drugs. 2007 Dec;16(12):1895-908. Review.
  • Au P, Daheron LM, Duda DG, Cohen KS, Tyrrell JA, Lanning RM, Fukumura D, Scadden DT, Jain RK.Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels.Blood. 2008 Feb 1;111(3):1302-5.
  • Willett CG, Duda DG, Czito BG, Bendell JC, Clark JW, Jain RK.Targeted therapy in rectal cancer.Oncology (Huntingt). 2007 Aug;21(9):1055-65; discussion 1065,. Review.
  • Duda DG,Jain RK,Willett CG.Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.J Clin Oncol. 2007 Sep 10;25(26):4033-42. Review.
  • Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT.Angiogenesis in brain tumours.Nat Rev Neurosci. 2007 Aug;8(8):610-22. Review.
  • Duda DG.American Association for Cancer Research 98th Annual Meeting. Angiogenesis and anti-angiogenesis in cancer.IDrugs. 2007 Jun;10(6):366-9.
  • Duda DG, Batchelor TT, Willett CG, Jain RK.VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects.Trends Mol Med. 2007 Jun;13(6):223-30.
  • Willett CG, Duda DG, di Tomaso E, Boucher Y, Czito BG, Vujaskovic Z, Vlahovic G, Bendell J, Cohen KS, Hurwitz HI, Bentley R, Lauwers GY, Poleski M, Wong TZ, Paulson E, Ludwig KA, Jain RK.Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.Nat Clin Pract Oncol. 2007 May;4(5):316-21.
  • Duda DG, Cohen KS, Scadden DT, Jain RK.A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood.Nat Protoc. 2007;2(4):805-10.
  • Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK.AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.Cancer Cell. 2007 Jan;11(1):83-95.
  • Willett CG, Kozin SV, Duda DG, di Tomaso E, Kozak KR, Boucher Y, Jain RK.Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice.Semin Oncol. 2006 Oct;33(5 Suppl 10):S35-40. Review.
  • Hagendoorn J,Padera TP,Yock TI,Nielsen GP,di Tomaso E,Duda DG,Delaney TF,Gaissert HA,Pearce J,Rosenberg AE,Jain RK,Ebb DH.Platelet-derived growth factor receptor-beta in Gorham's disease.Nat Clin Pract Oncol. 2006 Dec;3(12):693-7.
  • Duda DG.Antiangiogenesis and drug delivery to tumors: bench to bedside and back.Cancer Res. 2006 Apr 15;66(8):3967-70.
  • Duda DG, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT, Willett CG, Jain RK.Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy.J Clin Oncol. 2006 Mar 20;24(9):1449-53.
  • Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J, Wagner DD.Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage.Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):855-60.
  • Jain RK, Duda DG, Clark JW, Loeffler JS.Lessons from phase III clinical trials on anti-VEGF therapy for cancer.Nat Clin Pract Oncol. 2006 Jan;3(1):24-40. Review.
  • Duda DG, Cohen KS, Kozin SV, Perentes JY, Fukumura D, Scadden DT, Jain RK.Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors.Blood. 2006 Apr 1;107(7):2774-6.
  • Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY.Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.J Clin Oncol. 2005 Nov 1;23(31):8136-9.
  • Saito Y,Sunamura M,Motoi F,Abe H,Egawa S,Duda DG,Hoshida T,Fukuyama S,Hamada H,Matsuno S.Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region.Cancer Gene Ther. 2006 Mar;13(3):242-52.
  • Jain RK,Au P,Tam J,Duda DG,Fukumura D.Engineering vascularized tissue.Nat Biotechnol. 2005 Jul;23(7):821-3.
  • Stroh M, Zimmer JP, Duda DG, Levchenko TS, Cohen KS, Brown EB, Scadden DT, Torchilin VP, Bawendi MG, Fukumura D, Jain RK.Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo.Nat Med. 2005 Jun;11(6):678-82.
  • Duda DG,Jain RK.Pleiotropy of tissue-specific growth factors: from neurons to vessels via the bone marrow.J Clin Invest. 2005 Mar;115(3):596-8.
  • Duda DG,Fukumura D,Munn LL,Booth MF,Brown EB,Huang P,Seed B,Jain RK.Differential transplantability of tumor-associated stromal cells.Cancer Res. 2004 Sep 1;64(17):5920-4.
  • Duda DG,Fukumura D,Jain RK.Role of eNOS in neovascularization: NO for endothelial progenitor cells.Trends Mol Med. 2004 Apr;10(4):143-5.
  • Sunamura M,Lefter LP,Duda DG,Morita R,Inoue H,Yokoyama T,Yatsuoka T,Abe T,Egawa S,Furukawa T,Fukushige S,Oshimura M,Horii A,Matsuno S.The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma.Pancreas. 2004 Apr;28(3):311-6.
  • Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK.Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.Nat Med. 2004 Feb;10(2):145-7.
  • Duda DG,Sunamura M,Lefter LP,Furukawa T,Yokoyama T,Yatsuoka T,Abe T,Inoue H,Motoi F,Egawa S,Matsuno S,Horii A.Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells.Oncogene. 2003 Oct 9;22(44):6857-64.
  • Fukumura D,Ushiyama A,Duda DG,Xu L,Tam J,Krishna V,Chatterjee K,Garkavtsev I,Jain RK.Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis.Circ Res. 2003 Oct 31;93(9):e88-97.
  • Sunamura M,Duda DG,Ghattas MH,Lozonschi L,Motoi F,Yamauchi J,Matsuno S,Shibahara S,Abraham NG.Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer.Angiogenesis. 2003;6(1):15-24.
  • Jain RK,Duda DG.Role of bone marrow-derived cells in tumor angiogenesis and treatment.Cancer Cell. 2003 Jun;3(6):515-6.
  • Hoshida T,Sunamura M,Duda DG,Egawa S,Miyazaki S,Shineha R,Hamada H,Ohtani H,Satomi S,Matsuno S.Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor.Pancreas. 2002 Aug;25(2):111-21.
  • Sunamura M,Yatsuoka T,Motoi F,Duda DG,Kimura M,Abe T,Yokoyama T,Inoue H,Oonuma M,Takeda K,Matsuno S.Gene therapy for pancreatic cancer based on genetic characterization of the disease.J Hepatobiliary Pancreat Surg. 2002;9(1):32-8.
  • Lefter LP,Furukawa T,Sunamura M,Duda DG,Takeda K,Kotobuki N,Oshimura M,Matsuno S,Horii A.Suppression of the tumorigenic phenotype by chromosome 18 transfer into pancreatic cancer cell lines.Genes Chromosomes Cancer. 2002 Jun;34(2):234-42.
  • Duda DG,Sunamura M,Lozonschi L,Yokoyama T,Yatsuoka T,Motoi F,Horii A,Tani K,Asano S,Nakamura Y,Matsuno S.Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis.Br J Cancer. 2002 Feb 1;86(3):490-6.
  • Ding L,Sunamura M,Kodama T,Yamauchi J,Duda DG,Shimamura H,Shibuya K,Takeda K,Matsuno S.In vivo evaluation of the early events associated with liver metastasis of circulating cancer cells.Br J Cancer. 2001 Aug 3;85(3):431-8.
  • Sunamura M,Sun L,Lozonschi L,Duda DG,Kodama T,Matsumoto G,Shimamura H,Takeda K,Kobari M,Hamada H,Matsuno S.The antiangiogenesis effect of interleukin 12 during early growth of human pancreatic cancer in SCID mice.Pancreas. 2000 Apr;20(3):227-33.
  • Duda DG,Sunamura M,Lozonschi L,Kodama T,Egawa S,Matsumoto G,Shimamura H,Shibuya K,Takeda K,Matsuno S.Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12.Cancer Res. 2000 Feb 15;60(4):1111-6.
  • Motoi F,Sunamura M,Ding L,Duda DG,Yoshida Y,Zhang W,Matsuno S,Hamada H.Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus.Hum Gene Ther. 2000 Jan 20;11(2):223-35.